Evidence map›Paper›PMID 33168394›Full record

ArticleJournal of diabetes and its complications2021

Diabetes associated residual atherosclerotic cardiovascular risk in statin-treated patients with prior atherosclerotic cardiovascular disease.

Yanglu Zhao, Pin Xiang, Blai Coll, J Antonio G López, Nathan D Wong

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes and its complications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 17 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Yanglu ZhaoUniversity of California at Irvine, Heart Disease Prevention Program, Irvine, CA, USA; Department of Epidemiology, University of California Los Angeles, Los Angeles, CA, USA.
Pin XiangAmgen Inc., Thousand Oaks, CA, USA.
Blai CollAmgen Inc., Thousand Oaks, CA, USA.
J Antonio G LópezAmgen Inc., Thousand Oaks, CA, USA.
Nathan D WongUniversity of California at Irvine, Heart Disease Prevention Program, Irvine, CA, USA; Department of Epidemiology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: ndwong@uci.edu.
Amgen (United States) · USUniversity of California, Irvine · USUniversity of California, Los Angeles · US

Funding

AIM-HIGHU01HL081649 · NHLBI · AXIO RESEARCH, LLC · PI MCBRIDE, RUTH M · 2005 to 2010
$15.1M
AIM HIGH: Niacin Plus Statin to Prevent Vascular EventsU01HL081616 · NHLBI · UNIVERSITY OF WASHINGTON · PI PROBSTFIELD, JEFFREY LYNN · 2005 to 2010
$6.0M
NHLBI NIH HHS U01 HL081616NHLBI NIH HHS U01 HL081649
6 · The paper itself

Abstract

aimIn statin-treated persons with atherosclerotic cardiovascular disease (ASCVD) the further ASCVD risk that diabetes mellitus (DM) adds is not well-quantified. We examined this residual risk for initial and total recurrent ASCVD events.

methodsWe studied 3271 patients with ASCVD on statin therapy in the AIM-HIGH clinical trial cohort. Cox regression and the Prentice, Williams, and Peterson model examined the excess risk of initial and total recurrent ASCVD events associated with DM over a 3- year mean follow-up. Predictors of first and total ASCVD events in those with and without DM were also examined.

resultsOf our cohort with ASCVD on statin therapy 40% also had DM. Those with vs. without DM were older, were less likely to be male or white. They had higher systolic blood pressure, lower HDL-C, LDL-C, lipoprotein (a), but higher triglycerides and BMI (all p < 0.01). Adjusted HRs were 1.21 (95% CI; 1.01-1.46, p = 0.038) and 1.23 (95% CI: 1.05-1.44, p = 0.012) for first and total recurrent ASCVD events, respectively. Homocysteine and lipoprotein(a) most strongly predicted events in those with and without DM, respectively.

conclusionIn statin-treated patients with ASCVD, DM was associated with significantly greater residual risk over ASCVD alone for both first and total recurrent ASCVD events.

Indexed as

AtherosclerosisCardiovascular DiseasesDiabetes ComplicationsDiabetes MellitusHydroxymethylglutaryl-CoA Reductase InhibitorsCohort StudiesFemaleHeart Disease Risk FactorsHumansLipoprotein(a)MaleRisk AssessmentRisk FactorsHydroxymethylglutaryl-CoA Reductase InhibitorsLipoprotein(a)Cardiovascular diseaseDiabetes mellitusRisk assessmentStatins

Identifiers

PMID33168394
PMCPMC7870509
OpenAlexW3093566498

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.